Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer

Background/Aims: The benefit of second-line chemother­apy (SL) after failed first-line chemotherapy (FL) in patients with advanced pancreatic cancer has not yet been estab­lished. We evaluated the clinical characteristics affecting the benefits of SL compared to best supportive care (BSC), identifie...

Full description

Saved in:
Bibliographic Details
Published in:Gut and liver 2020-01, Vol.14 (1), p.135
Main Authors: Jeung Eun Lee, Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Si Young Song, Seungmin Bang
Format: Article
Language:Korean
Subjects:
Pancreatic neoplasms
Prognostic model
Second line chemothera­py
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aims: The benefit of second-line chemother­apy (SL) after failed first-line chemotherapy (FL) in patients with advanced pancreatic cancer has not yet been estab­lished. We evaluated the clinical characteristics affecting the benefits of SL compared to best supportive care (BSC), identified the prognostic factors, and ultimately devised a model of clinical parameters to assist in making decision be­tween SL and BSC after the failure of gemcitabine-based FL. Methods: The records of patients who received gemcitabine-based FL for advanced pancreatic cancer at Yonsei University Hospital between January 2010 and December 2015 were retrospectively reviewed. Significant clinical parameters were assessed for their potential as predictive factors. Results: SL patients received a longer duration of FL compared with BSC patients with median duration being 16.0 weeks (range, 8.0 to 26.0 weeks) and 8.0 weeks (range, 4.0 to 16.0 weeks), respectively (p
ISSN:1976-2283